Cellebrite DI Ltd.

NasdaqGS:CLBT Aktierapport

Börsvärde: US$3.2b

Cellebrite DI Förvaltning

Förvaltning kriterier kontrolleras 2/4

Cellebrite DI VD är Tom Hogan, utsedd i Dec 2024, har en mandatperiod på 1.42 år. totala årliga ersättningen är $ 10.80M, bestående av 4.8% lön 95.2% bonusar, inklusive företagsaktier och optioner. äger direkt 0.28% av företagets aktier, värda $ 9.02M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 1.4 år respektive 4.8 år.

Viktig information

Tom Hogan

Verkställande direktör

US$10.8m

Total ersättning

VD-lön i procent4.82%
Anställning som VD1.4yrs
Ägande av VD0.3%
Ledningens genomsnittliga anställningstid1.4yrs
Styrelsens genomsnittliga mandatperiod4.8yrs

Senaste uppdateringar av ledningen

Recent updates

CLBT: Updated Risk Profile And 2026 Guidance Will Support Premium P/E Potential

Analysts have trimmed their price targets on Cellebrite DI by $2. This reflects updated views on the stock's risk profile and valuation assumptions, while core growth and margin expectations remain largely unchanged.

CLBT: Updated Modeling And 2026 Guidance Will Support Premium P/E Potential

Cellebrite DI's analyst price targets have been trimmed by $2, with analysts linking the adjustment to updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts trimming their price targets by $2 are tying the move to refreshed views on discount rates, long term revenue growth, profit margins, and future P/E assumptions, rather than a single company specific event.

Cellebrite: A Rare SaaS Play Where AI Is A Tailwind, Not A Threat

Apr 06

CLBT: Refined Modeling And 2026 Guidance Will Support Premium P/E Potential

Analysts trimmed their price targets for Cellebrite DI by $2 to $21.67, citing updated assumptions on discount rate, long term revenue growth, profit margin and future P/E. These changes keep fair value broadly unchanged while slightly adjusting the risk and return profile.

CLBT: 2026 Revenue Guidance Will Support Earnings Power Despite P/E Recalibration

Analysts have trimmed their price targets on Cellebrite DI by $2, reflecting updated views on the stock's future P/E multiple and risk profile, while keeping key growth and profitability assumptions largely unchanged. Analyst Commentary Recent research updates suggest that analysts are adjusting their views on Cellebrite DI more around valuation mechanics than around its underlying business assumptions.

CLBT: Sustained Margins And 2026 Guidance Will Support Earnings Power

Analysts have adjusted their average price target on Cellebrite DI to about $21.67, down from the previous $24.71 level. The revised target reflects updated views on fair value, profit margins and future P/E assumptions following recent research updates from multiple firms.

CLBT: Higher Profitability Assumptions Will Support Stronger Medium Term Earnings Power

Analysts have raised their price target on Cellebrite DI from US$18.00 to US$23.00, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E as the key drivers of the change. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, with expected revenue between US$123 million and US$128 million and annual growth guidance of 13% to 17% (company guidance).

CLBT: Sustained Margins And 2025 ARR Guidance Will Support Earnings Power

Analysts have maintained their price target on Cellebrite DI at US$24.71, with only minor tweaks to inputs such as the discount rate and forward P/E, reflecting stable expectations around revenue growth and profit margin assumptions. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, targeting revenue of US$123 million to US$128 million, with annual growth of 13% to 17% (company guidance).

Cellebrite DI Ltd.'s (NASDAQ:CLBT) Shareholders Might Be Looking For Exit

Jan 13
Cellebrite DI Ltd.'s (NASDAQ:CLBT) Shareholders Might Be Looking For Exit

CLBT: Sustained Margin Strength Will Support Future Earnings Power

Analysts have maintained their fair value estimate for Cellebrite DI at US$24.71, making only minor adjustments to inputs such as the discount rate and long term P/E assumptions. This reflects a view that recent information does not materially alter their price outlook.

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, citing incremental improvements in the company’s discount rate assumptions and sustained expectations for high revenue growth and robust profit margins. What's in the News Cellebrite DI issued fourth quarter 2025 revenue guidance of $123 million to $128 million, implying year over year growth of 13% to 17% (company guidance).

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, reflecting slightly higher long term revenue growth and profit margin expectations that more than offset a marginally higher assumed discount rate and a modestly lower future P/E multiple. What's in the News Cellebrite DI issued revenue guidance for the fourth quarter of 2025, projecting between $123 million and $128 million, representing annual growth of 13% to 17% (company guidance).

CLBT: Profit Margins Will Drive Improved Earnings Outlook Into Next Year

Analysts have raised their price target for Cellebrite DI from $23.14 to $24.71. This change reflects increased confidence in the company’s stronger profit margins and revenue growth outlook.

Cloud SaaS Solutions Will Drive Digital Forensics Adoption

Cellebrite DI’s consensus price target was modestly raised to $23.14 as analysts anticipate near-term revenue softness due to U.S. federal budget constraints and delayed deal timing, while seeing future upside from eventual deal catch-up and FedRAMP progress. Analyst Commentary Slower-moving Q1 deals in Europe were completed in Q2, but persistent softness in U.S. federal deals is expected to continue until at least October, impacting near-term revenue.

What Cellebrite DI Ltd.'s (NASDAQ:CLBT) 26% Share Price Gain Is Not Telling You

Sep 09
What Cellebrite DI Ltd.'s (NASDAQ:CLBT) 26% Share Price Gain Is Not Telling You

Earnings Beat: Cellebrite DI Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 18
Earnings Beat: Cellebrite DI Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Cloud SaaS Solutions Will Drive Digital Forensics Adoption

Cellebrite DI’s consensus price target held steady at $23.00 as analysts factor in near-term headwinds from delayed federal spending and efficiency impacts, yet remain positive about long-term growth driven by healthy demand and anticipated federal certifications. Analyst Commentary Lowered Q2 results and second half guidance due to ongoing efficiency impacts and customer budget pauses.
User avatar

Cloud-Ready AI And Inseyets Migration Will Expand Digital Capabilities

Shift to cloud-based AI platforms and expansion in digital investigations are set to boost revenue through subscription services and high-margin solutions.

Cellebrite DI: A Compounder But Not Yet Priced For Conviction Buy

Apr 24

Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16
Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results

Cellebrite DI: Attractive Company In Connection With AI And Digital Investigation

Feb 04

A Look At The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)

Jan 10
A Look At The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)

Cellebrite: There Are Potential Risks That Could Damper Growth

Nov 08

Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?

Oct 30
Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?

There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased

Sep 10
There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased

Cellebrite: Rating Downgrade As Valuation Has Caught Up

Aug 27

Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up

Aug 17
Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up

Analys av ersättningar till VD

Hur har Tom Hogan:s ersättning förändrats jämfört med Cellebrite DI:s resultat?
DatumTotal ersättningLönFöretagets resultat
Dec 31 2025US$11mUS$520k

US$78m

Sep 30 2025n/an/a

US$76m

Jun 30 2025n/an/a

-US$151m

Mar 31 2025n/an/a

-US$194m

Dec 31 2024US$4mUS$150k

-US$283m

Ersättning vs marknad: Tom s total kompensation ($USD 10.80M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 7.11M ).

Ersättning vs inkomst: Ersättningen från Tom har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Tom Hogan (66 yo)

1.4yrs
Anställning
US$10,798,000
Kompensation

Mr. Thomas E. Hogan, also known as Tom, has been Director of Cellebrite DI Ltd. since August 2023 and had been Executive Chairman since August 2023 until January 1, 2025 and serves as its Chief Executive O...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Thomas Hogan
CEO & Director1.4yrsUS$10.80m0.28%
$ 9.0m
David Barter
Chief Financial Officerless than a yearUS$1.89m0.15%
$ 4.9m
Ronnen Armon
Chief Products & Technologies Officerless than a yearUS$1.47m0.11%
$ 3.6m
Marcus Jewell
Global Chief Revenue Officer2.5yrsUS$2.38m0.18%
$ 5.9m
Christopher Wade
Chief Technology Officerless than a yearinga uppgifter0.24%
$ 7.9m
Sigalit Shavit
Chief Information Officer1.8yrsinga uppgifter0.033%
$ 1.1m
Andrew Kramer
Vice President of Investor Relationsno datainga uppgifteringa uppgifter
Holly Windham
General Counsel & Chief Compliance Officerless than a yearinga uppgifter0.038%
$ 1.2m
David Gee
Chief Marketing Officer2.2yrsinga uppgifter0.059%
$ 1.9m
Zohar Tadmor-Eilat
Chief People Officer3.3yrsinga uppgifter0.052%
$ 1.7m
1.4yrs
Genomsnittlig anställningstid
57yo
Genomsnittlig ålder

Erfaren ledning: CLBT s ledningsgrupp anses inte vara erfaren ( 1.4 års genomsnittlig anställningstid), vilket föreslår ett nytt team.

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Thomas Hogan
CEO & Director2.8yrsUS$10.80m0.28%
$ 9.0m
Michael Capellas
Lead Independent Director1.3yrsinga uppgifter0.0071%
$ 231.5k
Dafna Gruber
Independent External Director4.8yrsinga uppgifter0.011%
$ 362.9k
Adam Clammer
Independent Chairman4.8yrsinga uppgifter0.33%
$ 10.5m
Troy Richardson
Independent Director1.8yrsinga uppgifter0.0084%
$ 272.7k
Brandon Van Buren
Independent Director3yrsinga uppgifter0.014%
$ 462.1k
Nadine Baudot-Trajtenberg
Independent External Director4.8yrsinga uppgifter0.014%
$ 462.1k
Yonatan Domnitz
Independent Director6.1yrsinga uppgifter0.024%
$ 790.3k
Ryusuke Utsumi
Independent Director6.1yrsinga uppgifter0.016%
$ 530.2k
Koby Huberman
Advisory Board Memberno datainga uppgifteringa uppgifter
4.8yrs
Genomsnittlig anställningstid
60yo
Genomsnittlig ålder

Erfaren styrelse: CLBT s styrelse anses vara erfaren ( 4.8 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/01 11:39
Aktiekurs vid dagens slut2026/05/01 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Cellebrite DI Ltd. bevakas av 9 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Tyler RadkeCitigroup Inc
Jeffrey Van RheeCraig-Hallum Capital Group LLC
Bhavin ShahDeutsche Bank